Cancellation of state registration. Atenolol Stade®

September 06, 2017
Active substances:
Trade names:
ICD-10:
IV.E00-E07.E05    Thyrotoxicosis [hyperthyroidism]
V.F40-F48.F45.3    Somatoform dysfunction of the autonomic nervous system
VI.G40-G47.G43    Migraine
IX.I10-I15.I10    Essential [primary] hypertension
IX.I20-I25.I20    Angina pectoris [angina pectoris]
IX.I20-I25.I20.0    Unstable angina
IX.I20-I25.I21    Acute myocardial infarction
IX.I30-I52.I42    Cardiomyopathy
IX.I30-I52.I47.1    Nadzheludochkovaya tachycardia
IX.I30-I52.I47.2    Ventricular tachycardia
IX.I30-I52.I48    Atrial fibrillation and flutter
IX.I30-I52.I49.4    Other and unspecified depolarization
Atenolol, treatment of arterial hypertension, ischemic heart disease, angina treatment, hypertensive crisis, arrhythmia, myocardial infarction

The Ministry of Health of the Russian Federation, in accordance with Article 32 of the Federal Law of 12.04.2010 No. 61-FZ "On the circulation of medicines", decided to abolish state registration and exclude from the state register of medicinal products for medical use of the medicinal product (registration certificate P N015683 / 01 from 17.03.2009 issued by STADA Artsnaymittel AG, Germany):

Atenolol Stade® (trade name of the medicinal product)

Atenolol (international non-proprietary, or grouping, or chemical name medicinal product)

tablets, 50 mg, 100 mg (dosage form, dosage)

STADA Arzneimittel AG, Germany Stadastrasse 2-18, D-61118, Bad Vilbel, Germany (name and address of the location of the manufacturer of the medicinal product)

on the basis of a filing by an authorized legal entity of Nizhpharm, Russia, of a request for the cancellation of the state registration of a medicinal product.